Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects.

Taskinen MR, Björnson E, Andersson L, Kahri J, Porthan K, Matikainen N, Söderlund S, Pietiläinen K, Hakkarainen A, Lundbom N, Nilsson R, Ståhlman M, Adiels M, Parini P, Packard C, Borén J.

J Clin Lipidol. 2019 Dec 12. pii: S1933-2874(19)30363-0. doi: 10.1016/j.jacl.2019.12.003. [Epub ahead of print]

PMID:
31917184
2.

The Association of Lipoprotein(a) Plasma Levels with Prevalence of Cardiovascular Disease and Metabolic Control Status in Patients with Type 1 Diabetes Mellitus.

Littmann K, Wodaje T, Alvarsson M, Bottai M, Eriksson M, Parini P, Brinck J.

Diabetes Care. 2019 Dec 20. pii: dc191398. doi: 10.2337/dc19-1398. [Epub ahead of print]

PMID:
31862789
3.

New insights from liver-humanized mice on cholesterol lipoprotein metabolism and LXR-agonist pharmacodynamics in humans.

Minniti ME, Pedrelli M, Vedin LL, Delbès AS, Denis RGP, Öörni K, Sala C, Pirazzini C, Thiagarajan D, Nurmi HJ, Grompe M, Mills K, Garagnani P, Ellis ECS, Strom SC, Luquet SH, Wilson EM, Bial J, Steffensen KR, Parini P.

Hepatology. 2019 Nov 30. doi: 10.1002/hep.31052. [Epub ahead of print]

PMID:
31785104
4.

Diiodothyronines regulate metabolic homeostasis in primary human hepatocytes by modulating mTORC1 and mTORC2 activity.

Gnocchi D, Ellis ECS, Johansson H, Eriksson M, Bruscalupi G, Steffensen KR, Parini P.

Mol Cell Endocrinol. 2020 Jan 1;499:110604. doi: 10.1016/j.mce.2019.110604. Epub 2019 Sep 30.

PMID:
31580898
5.

Subclinical atherosclerosis and its progression are modulated by PLIN2 through a feed-forward loop between LXR and autophagy.

Saliba-Gustafsson P, Pedrelli M, Gertow K, Werngren O, Janas V, Pourteymour S, Baldassarre D, Tremoli E, Veglia F, Rauramaa R, Smit AJ, Giral P, Kurl S, Pirro M, de Faire U, Humphries SE, Hamsten A; IMPROVE Study Group, Gonçalves I, Orho-Melander M, Franco-Cereceda A, Borén J, Eriksson P, Magné J, Parini P, Ehrenborg E.

J Intern Med. 2019 Dec;286(6):660-675. doi: 10.1111/joim.12951. Epub 2019 Jul 29.

6.

Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPARα.

Liang N, Damdimopoulos A, Goñi S, Huang Z, Vedin LL, Jakobsson T, Giudici M, Ahmed O, Pedrelli M, Barilla S, Alzaid F, Mendoza A, Schröder T, Kuiper R, Parini P, Hollenberg A, Lefebvre P, Francque S, Van Gaal L, Staels B, Venteclef N, Treuter E, Fan R.

Nat Commun. 2019 Apr 11;10(1):1684. doi: 10.1038/s41467-019-09524-z.

7.

Sex-specific lipid molecular signatures in obesity-associated metabolic dysfunctions revealed by lipidomic characterization in ob/ob mouse.

González-Granillo M, Helguero LA, Alves E, Archer A, Savva C, Pedrelli M, Ahmed O, Li X, Domingues MR, Parini P, Gustafsson JÅ, Korach-André M.

Biol Sex Differ. 2019 Feb 26;10(1):11. doi: 10.1186/s13293-019-0225-y.

8.

Genetic depletion of Soat2 diminishes hepatic steatosis via genes regulating de novo lipogenesis and by GLUT2 protein in female mice.

Ahmed O, Pramfalk C, Pedrelli M, Olin M, Steffensen KR, Eriksson M, Parini P.

Dig Liver Dis. 2019 Jul;51(7):1016-1022. doi: 10.1016/j.dld.2018.12.007. Epub 2018 Dec 23.

PMID:
30630736
9.

Ezetimibe in Combination With Simvastatin Reduces Remnant Cholesterol Without Affecting Biliary Lipid Concentrations in Gallstone Patients.

Ahmed O, Littmann K, Gustafsson U, Pramfalk C, Öörni K, Larsson L, Minniti ME, Sahlin S, Camejo G, Parini P, Eriksson M.

J Am Heart Assoc. 2018 Dec 18;7(24):e009876. doi: 10.1161/JAHA.118.009876.

10.

ERβ activation in obesity improves whole body metabolism via adipose tissue function and enhanced mitochondria biogenesis.

González-Granillo M, Savva C, Li X, Fitch M, Pedrelli M, Hellerstein M, Parini P, Korach-André M, Gustafsson JÅ.

Mol Cell Endocrinol. 2019 Jan 5;479:147-158. doi: 10.1016/j.mce.2018.10.007. Epub 2018 Oct 17.

PMID:
30342056
11.

Hepatic thyroid hormone receptor β1 agonism: good for lipids, good for bile?

Dawson PA, Parini P.

J Lipid Res. 2018 Sep;59(9):1551-1553. doi: 10.1194/jlr.C088955. Epub 2018 Jul 31. No abstract available.

12.

Inflammaging: a new immune-metabolic viewpoint for age-related diseases.

Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A.

Nat Rev Endocrinol. 2018 Oct;14(10):576-590. doi: 10.1038/s41574-018-0059-4. Review.

PMID:
30046148
13.

Overexpression of transforming growth factor β induced factor homeobox 1 represses NPC1L1 and lowers markers of intestinal cholesterol absorption.

Parini P, Melhuish TA, Wotton D, Larsson L, Ahmed O, Eriksson M, Pramfalk C.

Atherosclerosis. 2018 Aug;275:246-255. doi: 10.1016/j.atherosclerosis.2018.06.867. Epub 2018 Jun 19.

PMID:
29980051
14.

STK25 Regulates Cardiovascular Disease Progression in a Mouse Model of Hypercholesterolemia.

Cansby E, Magnusson E, Nuñez-Durán E, Amrutkar M, Pedrelli M, Parini P, Hoffmann J, Ståhlman M, Howell BW, Marschall HU, Borén J, Mahlapuu M.

Arterioscler Thromb Vasc Biol. 2018 Aug;38(8):1723-1737. doi: 10.1161/ATVBAHA.118.311241.

PMID:
29930001
15.

Potential Role of Thyroid Receptor β Agonists in the Treatment of Hyperlipidemia.

Jakobsson T, Vedin LL, Parini P.

Drugs. 2017 Oct;77(15):1613-1621. doi: 10.1007/s40265-017-0791-4. Review.

16.

Can LDL cholesterol be too low? Possible risks of extremely low levels.

Olsson AG, Angelin B, Assmann G, Binder CJ, Björkhem I, Cedazo-Minguez A, Cohen J, von Eckardstein A, Farinaro E, Müller-Wieland D, Parhofer KG, Parini P, Rosenson RS, Starup-Linde J, Tikkanen MJ, Yvan-Charvet L.

J Intern Med. 2017 Jun;281(6):534-553. doi: 10.1111/joim.12614. Review.

17.

Does statins promote vascular calcification in chronic kidney disease?

Chen Z, Qureshi AR, Parini P, Hurt-Camejo E, Ripsweden J, Brismar TB, Barany P, Jaminon AM, Schurgers LJ, Heimbürger O, Lindholm B, Stenvinkel P.

Eur J Clin Invest. 2017 Feb;47(2):137-148. doi: 10.1111/eci.12718.

PMID:
28036114
18.

The lipid droplet-associated protein perilipin 3 facilitates hepatitis C virus-driven hepatic steatosis.

Ferguson D, Zhang J, Davis MA, Helsley RN, Vedin LL, Lee RG, Crooke RM, Graham MJ, Allende DS, Parini P, Brown JM.

J Lipid Res. 2017 Feb;58(2):420-432. doi: 10.1194/jlr.M073734. Epub 2016 Dec 10.

19.

Intestinal PPARγ signalling is required for sympathetic nervous system activation in response to caloric restriction.

Duszka K, Picard A, Ellero-Simatos S, Chen J, Defernez M, Paramalingam E, Pigram A, Vanoaica L, Canlet C, Parini P, Narbad A, Guillou H, Thorens B, Wahli W.

Sci Rep. 2016 Nov 17;6:36937. doi: 10.1038/srep36937.

20.

Development of drug-loaded immunoliposomes for the selective targeting and elimination of rosetting Plasmodium falciparum-infected red blood cells.

Moles E, Moll K, Ch'ng JH, Parini P, Wahlgren M, Fernàndez-Busquets X.

J Control Release. 2016 Nov 10;241:57-67. doi: 10.1016/j.jconrel.2016.09.006. Epub 2016 Sep 13.

PMID:
27620073
21.

Changes in gluconeogenesis and intracellular lipid accumulation characterize uremic human hepatocytes ex vivo.

Li M, Ellis E, Johansson H, Nowak G, Isaksson B, Gnocchi D, Parini P, Axelsson J.

Am J Physiol Gastrointest Liver Physiol. 2016 Jun 1;310(11):G952-61. doi: 10.1152/ajpgi.00379.2015. Epub 2016 Apr 7.

22.

Impaired Cholesterol Efflux Capacity of High-Density Lipoprotein Isolated From Interstitial Fluid in Type 2 Diabetes Mellitus-Brief Report.

Apro J, Tietge UJ, Dikkers A, Parini P, Angelin B, Rudling M.

Arterioscler Thromb Vasc Biol. 2016 May;36(5):787-91. doi: 10.1161/ATVBAHA.116.307385. Epub 2016 Mar 31.

23.

Emerging role of thyroid hormone metabolites.

Gnocchi D, Steffensen KR, Bruscalupi G, Parini P.

Acta Physiol (Oxf). 2016 Jul;217(3):184-216. doi: 10.1111/apha.12648. Epub 2016 Jan 24. Review.

PMID:
26748938
24.

Effect of Statin Treatment on Plasma 4β-Hydroxycholesterol Concentrations.

Björkhem-Bergman L, Nylén H, Eriksson M, Parini P, Diczfalusy U.

Basic Clin Pharmacol Toxicol. 2016 Jun;118(6):499-502. doi: 10.1111/bcpt.12537. Epub 2016 Jan 14.

25.

Culturing of HepG2 cells with human serum improve their functionality and suitability in studies of lipid metabolism.

Pramfalk C, Larsson L, Härdfeldt J, Eriksson M, Parini P.

Biochim Biophys Acta. 2016 Jan;1861(1):51-59. doi: 10.1016/j.bbalip.2015.10.008. Epub 2015 Oct 26.

PMID:
26515253
26.

Levels of atherogenic lipoproteins are unexpectedly reduced in interstitial fluid from type 2 diabetes patients.

Apro J, Parini P, Broijersén A, Angelin B, Rudling M.

J Lipid Res. 2015 Aug;56(8):1633-9. doi: 10.1194/jlr.P058842. Epub 2015 Jun 19.

27.

RNA therapeutics inactivate PCSK9 by inducing a unique intracellular retention form.

Rocha CS, Wiklander OP, Larsson L, Moreno PM, Parini P, Lundin KE, Smith CI.

J Mol Cell Cardiol. 2015 May;82:186-93. doi: 10.1016/j.yjmcc.2015.03.009. Epub 2015 Mar 17.

28.

Lipids around the Clock: Focus on Circadian Rhythms and Lipid Metabolism.

Gnocchi D, Pedrelli M, Hurt-Camejo E, Parini P.

Biology (Basel). 2015 Feb 5;4(1):104-32. doi: 10.3390/biology4010104. Review.

29.

The TMAO-Generating Enzyme Flavin Monooxygenase 3 Is a Central Regulator of Cholesterol Balance.

Warrier M, Shih DM, Burrows AC, Ferguson D, Gromovsky AD, Brown AL, Marshall S, McDaniel A, Schugar RC, Wang Z, Sacks J, Rong X, Vallim TA, Chou J, Ivanova PT, Myers DS, Brown HA, Lee RG, Crooke RM, Graham MJ, Liu X, Parini P, Tontonoz P, Lusis AJ, Hazen SL, Temel RE, Brown JM.

Cell Rep. 2015 Jan 20;10(3):326-338. doi: 10.1016/j.celrep.2014.12.036. Epub 2015 Jan 15.

30.

The thyroid receptor β modulator GC-1 reduces atherosclerosis in ApoE deficient mice.

Kannisto K, Rehnmark S, Slätis K, Webb P, Larsson L, Gåfvels M, Eggertsen G, Parini P.

Atherosclerosis. 2014 Dec;237(2):544-54. doi: 10.1016/j.atherosclerosis.2014.09.035. Epub 2014 Oct 18.

PMID:
25463087
31.

Cholesterol, oxysterol, triglyceride, and coenzyme Q homeostasis in ALS. Evidence against the hypothesis that elevated 27-hydroxycholesterol is a pathogenic factor.

Wuolikainen A, Acimovic J, Lövgren-Sandblom A, Parini P, Andersen PM, Björkhem I.

PLoS One. 2014 Nov 21;9(11):e113619. doi: 10.1371/journal.pone.0113619. eCollection 2014.

32.

Role of TG-interacting factor (Tgif) in lipid metabolism.

Pramfalk C, Eriksson M, Parini P.

Biochim Biophys Acta. 2015 Jan;1851(1):9-12. doi: 10.1016/j.bbalip.2014.07.019. Epub 2014 Aug 1. Review.

PMID:
25088698
33.

Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation.

Degirolamo C, Modica S, Vacca M, Di Tullio G, Morgano A, D'Orazio A, Kannisto K, Parini P, Moschetta A.

Hepatology. 2015 Jan;61(1):161-70. doi: 10.1002/hep.27274. Epub 2014 Oct 30.

PMID:
24954587
34.

Hepatic ACAT2 knock down increases ABCA1 and modifies HDL metabolism in mice.

Pedrelli M, Davoodpour P, Degirolamo C, Gomaraschi M, Graham M, Ossoli A, Larsson L, Calabresi L, Gustafsson JÅ, Steffensen KR, Eriksson M, Parini P.

PLoS One. 2014 Apr 2;9(4):e93552. doi: 10.1371/journal.pone.0093552. eCollection 2014.

35.

TG-interacting factor 1 acts as a transcriptional repressor of sterol O-acyltransferase 2.

Pramfalk C, Melhuish TA, Wotton D, Jiang ZY, Eriksson M, Parini P.

J Lipid Res. 2014 Apr;55(4):709-17. doi: 10.1194/jlr.M045922. Epub 2014 Jan 29.

36.

Skeletal muscle as a target of LXR agonist after long-term treatment: focus on lipid homeostasis.

Archer A, Laurencikiene J, Ahmed O, Steffensen KR, Parini P, Gustafsson JÅ, Korach-André M.

Am J Physiol Endocrinol Metab. 2014 Mar 1;306(5):E494-502. doi: 10.1152/ajpendo.00410.2013. Epub 2013 Dec 24.

37.

The thyroid receptor modulator KB3495 reduces atherosclerosis independently of total cholesterol in the circulation in ApoE deficient mice.

Mörk LM, Rehnmark S, Davoodpour P, Norata GD, Larsson L, Witt MR, Malm J, Parini P.

PLoS One. 2013 Dec 4;8(12):e78534. doi: 10.1371/journal.pone.0078534. eCollection 2013.

38.

Estrogen receptor ligands ameliorate fatty liver through a nonclassical estrogen receptor/Liver X receptor pathway in mice.

Han SI, Komatsu Y, Murayama A, Steffensen KR, Nakagawa Y, Nakajima Y, Suzuki M, Oie S, Parini P, Vedin LL, Kishimoto H, Shimano H, Gustafsson JÅ, Yanagisawa J.

Hepatology. 2014 May;59(5):1791-802. doi: 10.1002/hep.26951. Epub 2014 Mar 27.

PMID:
24277692
39.

Mice with chimeric livers are an improved model for human lipoprotein metabolism.

Ellis EC, Naugler WE, Parini P, Mörk LM, Jorns C, Zemack H, Sandblom AL, Björkhem I, Ericzon BG, Wilson EM, Strom SC, Grompe M.

PLoS One. 2013 Nov 4;8(11):e78550. doi: 10.1371/journal.pone.0078550. eCollection 2013. Erratum in: PLoS One. 2014;9(7):e103870. Nauglers, Scott [corrected to Naugler, Willscott Edward].

40.

Is it possible to improve memory function by upregulation of the cholesterol 24S-hydroxylase (CYP46A1) in the brain?

Maioli S, Båvner A, Ali Z, Heverin M, Ismail MA, Puerta E, Olin M, Saeed A, Shafaati M, Parini P, Cedazo-Minguez A, Björkhem I.

PLoS One. 2013 Jul 16;8(7):e68534. doi: 10.1371/journal.pone.0068534. Print 2013.

41.

Serum apolipoprotein E as a marker to monitor graft function after hepatocyte transplantation in a clinically relevant mouse model.

Jorns C, Takahashi T, Callaghan E, Zemack H, Larsson L, Nowak G, Parini P, Ericzon BG, Ellis E.

Transplant Proc. 2013 Jun;45(5):1780-6. doi: 10.1016/j.transproceed.2013.01.032.

PMID:
23769043
42.

Atorvastatin treatment induces uptake and efflux transporters in human liver.

Björkhem-Bergman L, Bergström H, Johansson M, Parini P, Eriksson M, Rane A, Ekström L.

Drug Metab Dispos. 2013 Sep;41(9):1610-5. doi: 10.1124/dmd.113.051698. Epub 2013 Jun 10.

PMID:
23751277
43.

Increased expression of the very low-density lipoprotein receptor mediates lipid accumulation in clear-cell renal cell carcinoma.

Sundelin JP, Ståhlman M, Lundqvist A, Levin M, Parini P, Johansson ME, Borén J.

PLoS One. 2012;7(11):e48694. doi: 10.1371/journal.pone.0048694. Epub 2012 Nov 19.

44.

Fasting-induced FGF21 is repressed by LXR activation via recruitment of an HDAC3 corepressor complex in mice.

Archer A, Venteclef N, Mode A, Pedrelli M, Gabbi C, Clément K, Parini P, Gustafsson JÅ, Korach-André M.

Mol Endocrinol. 2012 Dec;26(12):1980-90. doi: 10.1210/me.2012-1151. Epub 2012 Oct 16.

45.

Influence of neonatal hypothyroidism on hepatic gene expression and lipid metabolism in adulthood.

Santana-Farré R, Mirecki-Garrido M, Bocos C, Henríquez-Hernández LA, Kahlon N, Herrera E, Norstedt G, Parini P, Flores-Morales A, Fernández-Pérez L.

PLoS One. 2012;7(5):e37386. doi: 10.1371/journal.pone.0037386. Epub 2012 May 16.

46.

SOCS2 deletion protects against hepatic steatosis but worsens insulin resistance in high-fat-diet-fed mice.

Zadjali F, Santana-Farre R, Vesterlund M, Carow B, Mirecki-Garrido M, Hernandez-Hernandez I, Flodström-Tullberg M, Parini P, Rottenberg M, Norstedt G, Fernandez-Perez L, Flores-Morales A.

FASEB J. 2012 Aug;26(8):3282-91. doi: 10.1096/fj.12-205583. Epub 2012 May 4.

PMID:
22562833
47.

LXRβ activation increases intestinal cholesterol absorption, leading to an atherogenic lipoprotein profile.

Hu X, Steffensen KR, Jiang ZY, Parini P, Gustafsson JÅ, Gåfvels M, Eggertsen G.

J Intern Med. 2012 Nov;272(5):452-64. doi: 10.1111/j.1365-2796.2012.02529.x. Epub 2012 Mar 26.

48.

Statins inhibit expression of thioredoxin reductase 1 in rat and human liver and reduce tumour development.

Skogastierna C, Johansson M, Parini P, Eriksson M, Eriksson LC, Ekström L, Björkhem-Bergman L.

Biochem Biophys Res Commun. 2012 Jan 20;417(3):1046-51. doi: 10.1016/j.bbrc.2011.12.091. Epub 2011 Dec 26.

PMID:
22222370
49.

Physical training increases osteoprotegerin in postmenopausal women.

Bergström I, Parini P, Gustafsson SA, Andersson G, Brinck J.

J Bone Miner Metab. 2012 Mar;30(2):202-7. doi: 10.1007/s00774-011-0304-6. Epub 2011 Aug 9.

PMID:
21823052
50.

Late cardiac tamponade by chylous pericardial effusion after coronary artery bypass surgery: case report.

Albåge A, Eggertsen G, Parini P.

Heart Surg Forum. 2011 Jun;14(3):E195-7. doi: 10.1532/HSF98.20101155.

PMID:
21676688

Supplemental Content

Loading ...
Support Center